Connect with us

Health

Foreign Aid Freeze Leaves Millions Without H.I.V. Treatment

Published

on

Foreign Aid Freeze Leaves Millions Without H.I.V. Treatment

Two weeks into President Trump’s sweeping freeze on foreign aid, H.I.V. groups abroad have not received any funding, jeopardizing the health of more than 20 million people, including 500,000 children. Subsequent waivers from the State Department have clarified that the work can continue, but the funds and legal paperwork to do so are still missing.

With the near closure of the American aid agency known as U.S.A.I.D. and its recall of officers posted abroad, there is little hope that the situation will resolve quickly, experts warned.

H.I.V. treatment and services were funded through the President’s Emergency Plan for AIDS Relief, or PEPFAR, a $7.5 billion program that was frozen along with all foreign aid on Mr. Trump’s first day in office.

Since its start in 2003 during the George W. Bush administration, PEPFAR has delivered lifesaving treatment to as many as 25 million people in 54 countries and had enjoyed bipartisan support. The program was due for a five-year reauthorization in 2023; it survived an effort by some House Republicans to end it and was renewed for one year.

Without treatment, millions of people with H.I.V. would be at risk of severe illness and premature death. The loss of treatment also threatens to reverse the dramatic progress made against H.I.V. in recent years and could spur the emergence of drug-resistant strains of H.I.V.; both outcomes could have a global impact, including in the United States.

Advertisement

The pause on aid and the stripping down of U.S.A.I.D. have delivered a “system shock,” said Christine Stegling, a deputy executive director at UNAIDS, the United Nations’ H.I.V. division.

“Now you need to see how you can work with the system as it is, to make sure that what is theoretically possible will actually happen,” she said.

On Jan. 28, Secretary of State Marco Rubio issued a waiver for lifesaving medicines and medical services, ostensibly allowing for the distribution of H.I.V. medicines. But the waiver did not name PEPFAR, leaving recipient organizations awaiting clarity.

On Sunday, another State Department waiver said more explicitly that it would cover H.I.V. testing and treatment as well as prevention and treatment of opportunistic infections such as tuberculosis, according to a memo viewed by The New York Times. The memo did not include H.I.V. prevention — except for pregnant and breastfeeding women — or support for orphaned and vulnerable children.

Although PEPFAR is funded by the State Department, roughly two-thirds of its grants are implemented through U.S.A.I.D. and the Centers for Disease Control and Prevention. Neither organization has released funds to grantees since the freeze was initiated.

Advertisement

In an interview with The Washington Post, Mr. Rubio appeared to blame the recipient organizations for not acting on the waiver, saying he had “real questions about the competence” of the groups. “I wonder whether they’re deliberately sabotaging it for purposes of making a political point,” he said.

But experts familiar with PEPFAR’s requirements said his comments belied the complexity of its system of approvals.

“The messaging and guidance from the State Department expose an ignorance of how these programs function — and an alarming lack of compassion for the millions of lives at risk,” said Jirair Ratevosian, who served as chief of staff for PEPFAR in the Biden administration.

For instance, the stop-work orders compelled each program to cease immediately. The organizations are now legally required to wait for equally explicit instructions and cannot proceed on the basis of a general memo, according to a senior official at a large global health organization that receives PEPFAR funds.

“We have to wait till we get individual letters on each project that tell us not only we can start work, but tell us which work we can start up and with how much money,” the official said. The official asked not to be named for fear of retaliation; 90 percent of the organization’s money comes from PEPFAR.

Advertisement

The freeze is also disrupting the network of smaller organizations that deliver H.I.V. treatment and services in low-income nations.

In a survey of 275 organizations in 11 sub-Saharan countries conducted over the past week, all reported that their programs or services had shut down or were turning people away, said Dr. Stellah Bosire, executive director of the Africa Center for Health Systems and Gender Justice.

At least 70 organizations reported disruptions in H.I.V. prevention, testing and treatment services, and 41 said that some programs had closed. “Without immediate intervention, these funding suspensions could lead to devastating reversals in public health progress,” Dr. Bosire said in an email.

In Kenya, 40,000 doctors, nurses and other health workers have been affected by the freeze, according to Mackenzie Knowles-Coursin, who was deputy chief of communications at the American mission in Nairobi until Monday. In South Africa, the halt in funding will affect the salaries of more than 15,000 health workers and operations across the country, the nation’s health minister, Aaron Motsoaledi, said during a televised news conference last week.

Some organizations rely on a patchwork of grants, with a stream of funding from one donor applied to purchasing medications and another stream applied to paying staff. Interruption of even one source can hobble the clinics, leaving them without medications to dispense or workers to dispense them.

Advertisement

The Uganda Key Populations Consortium, an umbrella organization that provides H.I.V. treatment and other services, has lost 70 percent of its funding. It has shuttered 30 of the 54 drop-in centers around the country that dispense medications, and it terminated the contracts of 28 of its 35 staff members.

The organization received about $200,000 per year from the C.D.C. via the Infectious Diseases Institute at Makerere University, as well as an $8 million grant over five years from U.S.A.I.D. The latter provided housing and employment assistance, including to gay and transgender people, and has been shut down to comply with Mr. Trump’s executive order on diversity, equity, inclusion and accessibility.

In 2023, Uganda enacted a sweeping law that criminalized consensual sex between same-sex adults and made same-sex relations while having H.I.V. punishable by death. It has caused scores of Ugandans to be evicted from homes and fired from jobs.

“Cases of human rights violations haven’t really slowed, and now it’s really concerning,” said Richard Lusimbo, director general of the Uganda Key Populations Consortium.

Richard Lusimbo in Kampala, Uganda, last year observing a hearing in Uganda’s constitutional court in which it upheld an anti-L.G.B.T.Q. law.Credit…Abubaker Lubowa/Reuters

“We don’t even have the capacity or even the tools that we need to actually respond to some of these issues,” he said.

Advertisement

Some organizations dispense medicines to children, which requires more skill than treating adults. Children’s medications are tailored to their age, weight and prior exposure to antiretroviral drugs, and the children must be carefully monitored for drug resistance.

In children who acquired H.I.V. at birth, the infection can progress very quickly to illness, with death occurring as early as eight to 12 weeks after birth — shorter than the 90-day pause on foreign aid.

On Tuesday night, the Trump administration put nearly all of U.S.A.I.D.’s global work force on leave and recalled those posted abroad to return to the United States within 30 days.

“There’s a loss of institutional memory, which may be purposeful, but it’s also creating just a backlog of paperwork, and it’s paralyzing the whole system,” said Elisha Dunn-Georgiou, the president of Global Health Council, a membership organization of health groups.

“Who do you ask questions to?” she said. “How do you move to the next step?”

Advertisement

Without U.S.A.I.D. staff to process waiver applications, organizations fear they will not see funds anytime soon. Even large global health organizations are struggling to stay afloat; some have already cut programs and staff.

Even if the funds return quickly, it may not be easy to restart programs and return to something resembling normalcy, Ms. Dunn-Georgiou said.

“It costs a lot to restart something, so I don’t think we really know yet if that’s even possible,” she said.

Lynsey Chutel and Stephanie Nolen contributed reporting.

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Health

Trump’s Focus on Punishing Drug Dealers May Hurt Drug Users Trying to Quit

Published

on

Trump’s Focus on Punishing Drug Dealers May Hurt Drug Users Trying to Quit

President Trump has long railed against drug traffickers. He has said they should be given the death penalty “for their heinous acts.” On the first day of his second term, he signed an executive order listing cartels as “terrorist organizations.”

But many public health and addiction experts fear that his budget proposals and other actions effectively punish people who use drugs and struggle with addiction.

The Trump administration has vowed to reduce overdose deaths, one of the country’s deadliest public health crises, by emphasizing law enforcement, border patrols and tariffs against China and Mexico to keep out fentanyl and other dangerous drugs. But it is also seeking huge cuts to programs that reduce drug demand.

The budget it submitted to Congress this month seeks to eliminate more than a billion dollars for national and regional treatment and prevention services. The primary federal agency addressing drug use, the Substance Abuse and Mental Health Services Administration, has so far lost about half its workers to layoffs under the Trump administration and is slated to be collapsed into the new Administration for a Healthy America, whose purview will reach far beyond mental illness and drug use.

And if reductions to Medicaid being discussed by Republicans in Congress are realized, millions of Americans will be unable to continue, much less start treatment.

Advertisement

The White House did not respond to requests for comment. The budget itself says that ending drug trafficking “starts with secure borders and a commitment to law and order” and that it is cutting addiction services deemed duplicative or “too small to have a national impact.”

Those cuts are agonizing, public health experts say, because they come just as the country is making sustained progress in lowering the number of fentanyl deaths. Many interventions may be contributing to that progress, including greater availability of the overdose reversal spray naloxone; more treatment beds, sober housing and peer counseling; and declines in the strength and quantity of the illicit drug supply, they say. But studies so far have not demonstrated convincingly which of those factors merit greater focus and investment.

“It would be a tragedy if we defund these programs without fully understanding what’s working and then our overdose rate starts to climb again,” said Dr. Matthew Christiansen, an addiction medicine physician in Huntington, W.Va., a city once labeled ground zero for the opioid crisis.

A letter signed by more than 320 behavioral medicine academic experts, sent Monday to congressional leaders, decried the cuts, including those to “community-based naloxone distribution, peer outreach programs, drug-use-related infectious disease prevention programs and drug test strip programs.”

The president’s budget calls for ending grants for “harm reduction,” a strategy to prevent disease transmission and keep drug users alive that has become largely accepted by mainstream addiction treatment providers.

Advertisement

The budget derides federal financial support for “dangerous activities billed as ‘harm reduction,’ which included funding ‘safe smoking kits and supplies’ and ‘syringes’ for drug users.”

That language is a callback to false reports in 2022 that a $30 million federal harm reduction grant could be used to purchase pipes for smoking crack and meth. In fact, a small portion of that grant, designated for “safer smoking kits,” was for supplies like alcohol swabs and lip balm. The grant also supported programs in states that permit sterile syringe exchanges, effective in reducing hepatitis C and H.I.V. infection rates.

“You can’t just tell people to stop using drugs with a snap of the fingers,” said Dr. Christiansen, a former director of West Virginia’s drug control policy. “These are tools to reduce the harm of opioids while also helping them be successful long-term.”

According to the federal agency’s annual survey of substance use, in 2023, 27.2 million Americans ages 12 or older had a drug use disorder, 28.9 million had alcohol use disorder, and 7.5 million had both.

The budget does leave intact block grants for states to combat addiction and mental illness. But without the agency’s additional grants, hands-on training and monitoring, in addition to possible Medicaid reductions, states will not be able to afford the many medical and social services required to prevent and treat addiction, Dr. Christiansen said.

Advertisement

David Herzberg, a professor of drug policy and history at the University at Buffalo, said that Mr. Trump’s almost single-minded linking of the nation’s drug problems with border issues harks back to late 19th-century America, when the government associated opium dens with Chinese immigrants. Fearing the incursion of Chinese workers and inflamed by press reports of Chinese men using opium to lure young white women into prostitution, Congress severely restricted Chinese immigration.

Then as now, Mr. Herzberg said, political conservatives found that targeting foreign drug suppliers was a muscular means of advancing broader agendas.

In contrast with highly publicized drug seizures, people who chronically use drugs have become afterthoughts, usually visible only as street irritants, their addiction perceived to be the result of their own choices, he said. Elected leaders who advocate for their welfare risk being tarred as soft on crime.

“If politicians are going to stick their necks out for them, I would be shocked,” Mr. Herzberg said.

Advertisement
Continue Reading

Health

FDA warns seniors to avoid this vaccine after deadly complications

Published

on

FDA warns seniors to avoid this vaccine after deadly complications

Older adults are being warned against receiving the chikungunya vaccine before traveling.

The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.

Advertisement

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus.

FIRST VACCINE FOR CHIKUNGUNYA VIRUS, AN ‘EMERGING GLOBAL HEALTH THREAT,’ GETS FDA APPROVAL

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

“FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq,” the release reads. 

Older adults are being warned against receiving the chikungunya vaccine before traveling. (iStock)

Advertisement

“While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue.”

The advisory follows reports of “serious adverse events,” including neurologic and cardiac events in people who received the vaccine.

    

Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated.

Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89.

Advertisement
A patient infected with chikungunya

A patient infected with chikungunya looks out from mosquito netting at the Clinicas Hospital in San Lorenzo, Paraguay, in March 2023. The FDA warned that Ixchiq, which contains a live, weakened version of the virus, may cause similar symptoms to chikungunya. (AP Photo/Jorge Saenz)

The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus.

Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Most people recover within a week, but some may experience “severe and disabling” joint pain for weeks or months. 

mosquito sucking blood from human

Chikungunya is spread by the bite of infected mosquitoes. (iStock)

“This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes,” Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital.

Advertisement

At the time of the vaccine’s approval, the FDA described chikungunya as an “emerging global health threat,” with at least five million cases reported over the past 15 years. 

For more Health articles, visit www.foxnews.com/health

The FDA plans to conduct an “updated benefit-risk assessment” for Ixchiq use in those over 60 years of age, according to the notice.

Fox News Digital’s Melissa Rudy contributed to this report.

Advertisement
Continue Reading

Health

Lose Weight up to 8x Faster With a ‘Green’ Diet for Fatty Liver

Published

on

Lose Weight up to 8x Faster With a ‘Green’ Diet for Fatty Liver


Advertisement


Diet for Fatty Liver: How to Lose Weight Faster and Easier | Woman’s World




















Advertisement











Advertisement




Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading
Advertisement

Trending